Medimmune Limited

Maria Aleksandra Bednarek

Ronald Henry Jackson

David Fairman

Madeleine Antonsson

Lambertus Benthem

Jacqueline Metcalfe

Balaji Agoram

Maria Fritsch-Fredin

Nicole Burmeister

Rasmus Jansson Lofmark

Lutz Jermutus

Philip Ambery

Marcella Petrone

Jefferson Revell

Sivaneswary Genapathy

Jefferson D Revell

Jaqueline Metcalfe

Ronald Jackson

Lutz Ulrich Jermutus

Disclosed are polypeptides which are pramlintide analogues and uses thereof. In particular, the present invention relates to polypeptides of SEQ ID NO 2 which are pramlintide analogues conjugated to half-life extending moieties such as albumin binding moieties and uses thereof.

Polypeptides and uses thereof

This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.

Glucagon/GLP-1 agonists for the treatment of obesity

Provided herein are methods of preventing and treating obesity and diabetes in patients comprising administering GLP-1/glucagon agonists peptides.

Glucagon and GLP-1 co-agonists for the treatment of obesity

The present invention provides protease-resistant peptides, methods of making such peptides, as well as compositions comprising protease-resistant peptides and method of treatment utilizing such peptides. A combination of lipidation of certain amino acid residues and substitution of alpha-methyl functionalized amino acids for natural amino acids has been determined to produce protease-resistant peptides.

Protease-resistant lipidated GLP-1 analogs

This disclosure provides pegylated GLP-1/glucagon agonist peptides for the treatment of metabolic diseases, e.g., obesity.

Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity

Growing community of inventors

Cambridge, United Kingdom

Maria Aleksandra Bednarek